Table 1.
Baseline characteristics of patients
| LEN monotherapy (n = 39) |
LEN combination (n = 72) |
LEN + PD1 (n = 30) |
LEN + HAIF/TACE (n = 24) |
LEN + PD1 + HAIF/TACE (n = 16) |
|
|---|---|---|---|---|---|
| Age (Median ± SE) | 50 ± 13.3 | 51 ± 11.9 | 50.5 ± 10.6 | 55 ± 13.1 | 50 ± 12.8 |
| Gender (Male/Female) | 37/2 | 66/6 | 28/2 | 23/1 | 13/3 |
| BCLC stage (A/B/C) | 6/11/22 | 11/14/47 | 5/5/20 | 3/5/16 | 3/3/10 |
| HBV infection (Yes/No) | 33/6 | 65/7 | 28/2 | 22/2 | 13/3 |
| AFP (ng/ml) (< 400/> 400) | 24/15 | 33/39 | 15/15 | 9/15 | 8/8 |
| Median follow-up (week) | 44.7 | 45.1 | 48.9 | 45.2 | 36.4 |
| Child-Pugh (A/B) | 7/32 | 7/65 | 4/26 | 2/24 | 16/16 |
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HAIF, hepatic arterial infusion with drug filtration; HBV, hepatitis B virus; LEN, lenvatinib; PD1, programmed cell death protein-1; TACE, transcatheter arterial chemoembolization